APLM MEXC RealStocks
Own real APLM shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:20:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Apollomics Inc. (APLM) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $16.94, with a market capitalization of $49.09M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.58 to $28.29. This page covers its latest market performance, valuation, price trends and company information.
$49.09M | |
$16.60 | |
$17.54 | |
$16.22 | |
$16.84 | |
9.89K | |
13.38K | |
-- | |
$28.29 | |
$12.58 | |
-- | |
2026-06-30 |
Apollomics Inc. (APLM) last closed at $16.94 as of 2026-11-19 00:31:00, up 2.07% ($0.34) from the previous close of $16.84.
During the latest regular trading session, APLM traded between $16.22 and $17.54, with a volume of 9.89K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Apollomics Inc. (APLM) moved from $18.25 to $16.94, representing a decline of 7.18% ($1.31).
The stock traded between $16.22 and $20.11 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 11.44 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 27.7%
APLM is currently trading at $16.94, placing it 27.7% of the way from its 52-week low of $12.58 to its 52-week high of $28.29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Apollomics Inc. (APLM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to APLM, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between APLM shares and USD.
APLM Shares to USD
1.00 APLM shares = 16.939 USD
Calculations are estimates based on the latest available price and are for reference only.